PRIMARY STUDY
Dual therapy targeting the endocannabinoid system prevents experimental diabetic nephropathy.
Key Findings: 'Peripheral' CB1R blockade is beneficial in experimental DN and this effect is synergically magnified by CB2R activation.
Type of Study: Animal Study
Study Result: Positive
Study Location(s): Italy, United States
Year of Pub: 2017
Cannabinoids Studied: AM-x Synthetic Cannabinoids
Phytocannabinoid Source: Not Applicable
Receptors Studied: CB1, CB2
